Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ABEO | US
0.23
3.69%
Healthcare
Biotechnology
30/06/2024
04/10/2024
6.46
6.42
6.60
6.42
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101 an autologous engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York New York.
View LessLow Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
54.3%1 month
46.6%3 months
54.7%6 months
100.3%-
-
3.48
0.32
0.17
-0.58
53.29
-
-54.75M
279.81M
279.81M
-
-
-
-100.00
-127.38
12.08
6.27
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.91
Range1M
1.28
Range3M
2.31
Rel. volume
0.77
Price X volume
1.19M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PEPG | PEPG | Biotechnology | 9.3 | 303.08M | 2.88% | n/a | 12.52% |
Kamada Ltd | KMDA | Biotechnology | 5.2 | 298.89M | -0.57% | 20.04 | 3.41% |
STROUDS INC | STRO | Biotechnology | 3.61 | 295.89M | 2.85% | n/a | 125.14% |
Aviragen Therapeutics Inc | AVIR | Biotechnology | 3.46 | 292.10M | 2.67% | n/a | 0.43% |
THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 5.51 | 291.89M | 5.15% | n/a | 35.68% |
Ocugen Inc | OCGN | Biotechnology | 1.01 | 290.74M | 4.12% | n/a | 40.56% |
Lexeo Therapeutics Inc. Common Stock | LXEO | Biotechnology | 8.66 | 286.31M | -0.69% | n/a | 6.58% |
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 5 | 283.10M | 0.60% | n/a | 1.03% |
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 16.04 | 282.22M | -3.32% | n/a | -201.68% |
Akebia Therapeutics Inc | AKBA | Biotechnology | 1.33 | 279.68M | -0.75% | n/a | -309.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.58 | 0.76 | Cheaper |
Ent. to Revenue | 53.29 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.48 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 54.74 | 74.67 | Lower Risk |
Debt to Equity | 0.32 | -1.82 | Expensive |
Debt to Assets | 0.17 | 0.26 | Cheaper |
Market Cap | 279.81M | 3.73B | Emerging |